In his workshop, Alfred Radauer will further focus on the topics of his talk: What are the basic functioning principles of the IP and patent system in the pharma and biotech sector? What are motives and strategic approaches to use patents and other forms of IP? What are downsides and challenges of using IP in the sector? What are on-going issues (e.g., second medical use patents; gene patents; etc.)? And what are the implications for persons being employed in the sector or starting up a company?